Telitacicept named orphan drug in EU as myasthenia gravis therapy
The anti-inflammatory therapy telitacicept for myasthenia gravis was granted orphan drug status in the EU by the European Medicines Agency.| Myasthenia Gravis News
The anti-inflammatory therapy telitacicept for myasthenia gravis was granted orphan drug status in the EU by the European Medicines Agency.| Myasthenia Gravis News
Zilbrysq was found safe and effective in a clinical trial for generalized myasthenia gravis patients who switched from other C5 inhibitors.| Myasthenia Gravis News
Povetacicept reduced disease activity in a mouse model of MG by reducing the levels of disease-causing antibodies in the bloodstream.| Myasthenia Gravis News
Vor Bio signed an exclusive license agreement to develop and market Remegen’s telitacicept for MG outside China, Hong Kong, Macau, and Taiwan.| Myasthenia Gravis News
Thymectomy led to a long-term reduction in the levels of immune T-cells and to temporary changes in cytokine levels in MG patients.| Myasthenia Gravis News
Two women with severe, treatment-resistant MG responded well to the cancer medication blinatumomab, according to a case report.| Myasthenia Gravis News
Lindsey Shapiro is a science writer for Myasthenia Gravis News with a PhD in neuroscience. She covers the latest news and information on a variety of myasthenia gravis topics.| Myasthenia Gravis News
Margarida Maia is a science writer for Myasthenia Gravis News with a PhD in biomedical sciences. She covers the latest news and information on a variety of myasthenia gravis topics.| Myasthenia Gravis News
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Myasthenia Gravis News
Category archive page for News.| Myasthenia Gravis News
